C4 Therapeutics, Inc. (CCCC) Debt Components
- 2023-12-31: Long-term Debt, Current MaturitiesUSD $0.00; Long-term Debt, Excluding Current MaturitiesUSD $0.00; Long-term DebtUSD (m); Long-Term Debt, Maturity, Year OneUSD (m).
- 2023-09-30: Long-term Debt, Current MaturitiesUSD $0.00; Long-term Debt, Excluding Current MaturitiesUSD $0.00; Long-term DebtUSD (m); Long-Term Debt, Maturity, Year OneUSD (m).
- 2023-06-30: Long-term Debt, Current MaturitiesUSD $10.34M; Long-term Debt, Excluding Current MaturitiesUSD $0.00; Long-term DebtUSD $10.34M; Long-Term Debt, Maturity, Year OneUSD $9.50M.
- 2023-03-31: Long-term Debt, Current MaturitiesUSD $2.29M; Long-term Debt, Excluding Current MaturitiesUSD $8.62M; Long-term DebtUSD $11.75M; Long-Term Debt, Maturity, Year OneUSD $9.50M.
C4 Therapeutics, Inc. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Long-term Debt, Current Maturities USD | Long-term Debt, Excluding Current Maturities USD | Long-term Debt USD | Long-Term Debt, Maturity, Year One USD | Long-Term Debt, Maturity, Year Two USD | Long-Term Debt, Maturity, Year Three USD | Long-Term Debt, Maturity, Year Four USD | Long-Term Debt, Maturity, Remainder of Fiscal Year USD | Long-term Debt, Gross USD | Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net USD |
|---|---|---|---|---|---|---|---|---|---|---|
| 2023-12-31 | $0.00 | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $0.00 | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $10.34M | $0.00 | $10.34M | $9.50M | (m) | (m) | (m) | $1.50M | $11.00M | $665.00K |
| 2023-03-31 | $2.29M | $8.62M | $11.75M | $9.50M | (m) | (m) | (m) | $2.25M | $11.75M | $129.00K |
| 2022-12-31 | $2.29M | $9.20M | $11.48M | (m) | (m) | (m) | (m) | (m) | (m) | $1.02M |
| 2022-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $12.50M | (m) |
| 2022-12-31 | (m) | (m) | (m) | $3.00M | $9.50M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $2.25M | $9.05M | $11.30M | $3.00M | $9.50M | (m) | (m) | $0.00 | $12.50M | $1.20M |
| 2022-06-30 | $750.00K | $10.37M | $11.12M | $3.00M | $9.50M | (m) | (m) | $0.00 | $12.50M | $1.38M |
| 2022-03-31 | $750.00K | $10.19M | $10.94M | $3.00M | $9.50M | (m) | (m) | (m) | $12.50M | $1.56M |
| 2021-12-31 | $0.00 | $10.77M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | (m) | $10.77M | (m) | $3.00M | $9.50M | (m) | (m) | $12.50M | $1.73M |
| 2021-09-30 | (m) | $10.59M | $10.59M | (m) | $3.00M | $9.50M | (m) | (m) | $12.50M | $1.91M |
| 2021-06-30 | (m) | $10.41M | $10.41M | (m) | $3.00M | $9.50M | (m) | (m) | $12.50M | $2.09M |
| 2021-03-31 | (m) | $10.23M | $10.23M | (m) | $3.00M | $9.50M | (m) | (m) | $12.50M | $2.27M |
| 2020-12-31 | (m) | $10.05M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | $10.05M | (m) | (m) | $3.00M | $9.50M | (m) | $12.50M | $2.45M |
| 2020-09-30 | (m) | $9.88M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |